• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤ 1.5 times ULN) • Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: • Presence of active / uncontrolled central nervous system involvement • History of clinically significant cardiac disease; uncontrolled hypertension • Left ventricular ejection fraction (LVEF) < 45 % • Allogeneic stem cell transplant within 100 days before first dose of study drug • Known history of human
immunodeficiency virus (HIV) infection • Chronic or active hepatitis B or C, requiring antiviral therapy • Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from
prior therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days
prior to the start of study treatment and for the duration of the study
The impact of the full program (prenatal and infancy home visitation) on children's use of alcohol and number of sexual partners is important because recent evidence indicates that alcohol use
prior to age 15 years multiplies the risk of alcoholism in adulthood26 and multiple partners increase the risk for sexually transmitted diseases, including human
immunodeficiency virus infection.27, 28 The effect of the program on alcohol use is consistent with greater alcohol consumption observed among adult rhesus monkeys who experienced aberrant rearing.29 These findings must be tempered, however, with an acknowledgment of their limitations.